Galecto Inc (GLTO)

Nov 1, 2024, 8:30 AM EDT - 2 months ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 3 months ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 3 months ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 5 months ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 9 months ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 1 year ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 1 year ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 1 year ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 1 year ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 1 year ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 1 year ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 1 year ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 1 year ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 1 year ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 1 year ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 1 year ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 1 year ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 1 year ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 1 year ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 1 year ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 2 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 2 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 2 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 2 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 2 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 2 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 2 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 2 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 2 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 2 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 2 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 2 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 2 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 2 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Feb 17, 2022, 5:00 PM EST - 3 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

Jan 27, 2022, 7:00 AM EST - 3 years ago

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Dec 13, 2021, 8:00 AM EST - 3 years ago

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Nov 2, 2021, 11:26 AM EDT - 3 years ago

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Nov 2, 2021, 8:00 AM EDT - 3 years ago

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Oct 26, 2021, 8:00 AM EDT - 3 years ago

Galecto to Present at Upcoming Investor Conferences

Sep 15, 2021, 8:30 AM EDT - 3 years ago

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

Sep 13, 2021, 8:00 AM EDT - 3 years ago

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Aug 18, 2021, 9:25 AM EDT - 3 years ago

Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial

Aug 18, 2021, 8:00 AM EDT - 3 years ago

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)

Jul 16, 2021, 9:12 AM EDT - 3 years ago

3 Net Current Asset Value Stock Picks

DSS SVRA